Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences and keeping the price target at $50.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily centered around the promising data from Assembly Biosciences’ interim Phase 1b trials for ABI-5366. This long-acting oral helicase-primase inhibitor has shown significant antiviral activity and favorable tolerability, which supports its progression to Phase 2 trials. The data presented at the International Union Against Sexually Transmitted Infections Congress highlighted the drug’s potential as a best-in-class therapy for recurrent genital herpes, with impressive reductions in HSV-2 shedding and genital lesion rates.
Furthermore, the pharmacokinetic profile of ABI-5366 supports both weekly and potentially monthly dosing, offering a convenient treatment option that could appeal to patients dissatisfied with current daily therapies. The drug was well tolerated, with no serious adverse events reported, reinforcing its safety profile. Given the substantial market opportunity in the U.S. for a once-monthly oral therapy, Trucchio values ABI-5366 at $21 per share, contributing to his Buy rating and a price target of $50 for Assembly Biosciences’ stock.